AR069438A1 - Formulaciones en solucion que contienen clorhidrato de moxifloxacina y fosfato de dexametasona para uso oftalmico u otico por via topica - Google Patents
Formulaciones en solucion que contienen clorhidrato de moxifloxacina y fosfato de dexametasona para uso oftalmico u otico por via topicaInfo
- Publication number
- AR069438A1 AR069438A1 ARP080105164A ARP080105164A AR069438A1 AR 069438 A1 AR069438 A1 AR 069438A1 AR P080105164 A ARP080105164 A AR P080105164A AR P080105164 A ARP080105164 A AR P080105164A AR 069438 A1 AR069438 A1 AR 069438A1
- Authority
- AR
- Argentina
- Prior art keywords
- ophthalmic
- phosphate
- moxifloxacine
- dexametasone
- chlorhydrate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 title abstract 3
- 229960003702 moxifloxacin Drugs 0.000 title abstract 3
- 230000000699 topical effect Effects 0.000 title abstract 3
- 229910019142 PO4 Inorganic materials 0.000 title 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 abstract 3
- 229960004833 dexamethasone phosphate Drugs 0.000 abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 229960000686 benzalkonium chloride Drugs 0.000 abstract 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract 1
- 239000004327 boric acid Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se dan a conocer composiciones oftálmicas y oticas de moxifloxacina y fosfato de dexametasona en solucion para uso topico. Reivindicacion 1: Una composicion en solucion acuosa, conservada, multidosis, administrable por vía topica para uso oftálmico u otico constituida básicamente por a) 0,5 - 0,6% (p/v) de moxifloxacina o una de sus sales aceptables para uso farmacéutico; b) 0,10 - 0,12% (p/v) de fosfato de dexametasona o una de sus sales aceptables para uso farmacéutico en una cantidad equivalente a 0,10 - 0,12% (p/v) de fosfato de dexametasona; c) 0,005 - 0,02% (p/v) de edetato disodico; d) 0,5 - 0,75% (p/v) de cloruro de sodio; e) 0,2 - 0,4% (p/v) de ácido borico; f) o bien 0,1 - 0,3% (p/v) de sorbitol o bien 0,005 - 0,015% de cloruro de benzalconio; g) un surfactante no ionico en una cantidad de 0,04 -0,06% (p/v); h) un agente regulador del pH en una cantidad suficiente para hacer que la composicion tenga un pH 7,5 - 8,1; y i) agua.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99045207P | 2007-11-27 | 2007-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069438A1 true AR069438A1 (es) | 2010-01-20 |
Family
ID=40467276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105164A AR069438A1 (es) | 2007-11-27 | 2008-11-27 | Formulaciones en solucion que contienen clorhidrato de moxifloxacina y fosfato de dexametasona para uso oftalmico u otico por via topica |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7888370B2 (es) |
| EP (1) | EP2211835A1 (es) |
| JP (1) | JP2011504881A (es) |
| KR (1) | KR20100090278A (es) |
| CN (1) | CN101861139A (es) |
| AR (1) | AR069438A1 (es) |
| AU (1) | AU2008329876A1 (es) |
| BR (1) | BRPI0819908A2 (es) |
| CA (1) | CA2703913A1 (es) |
| CL (1) | CL2008003536A1 (es) |
| MX (1) | MX2010004953A (es) |
| RU (1) | RU2010126096A (es) |
| TW (1) | TW200932285A (es) |
| UY (1) | UY31494A1 (es) |
| WO (1) | WO2009070530A1 (es) |
| ZA (1) | ZA201002884B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
| WO2013065029A1 (en) * | 2011-11-04 | 2013-05-10 | Micro Labs Limited | Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections |
| ITMI20122002A1 (it) * | 2012-11-26 | 2014-05-27 | Farmacologico Milanese Srl Lab | Preparazioni farmaceutiche liquide stabilizzate |
| WO2014119643A1 (ja) | 2013-01-31 | 2014-08-07 | 千寿製薬株式会社 | 澄明な水性液剤 |
| US20160279055A1 (en) | 2013-07-22 | 2016-09-29 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| US20150164882A1 (en) | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US10130639B1 (en) * | 2015-09-05 | 2018-11-20 | Randal Davis | Homogeneous ophthalmic composition |
| US11452732B2 (en) | 2015-09-05 | 2022-09-27 | Randal Davis | Homogeneous ophthalmic composition |
| GR1008921B (el) * | 2015-12-10 | 2017-01-12 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δεξαμεθαζονη |
| KR20190109604A (ko) * | 2016-05-06 | 2019-09-25 | 해로우 헬스 인코포레이티드 | 약학적 안과용 조성물 및 그의 제조 방법 |
| US20190216830A1 (en) * | 2017-10-06 | 2019-07-18 | Aciont Inc. | Ophthalmic compositions |
| CN113750041A (zh) * | 2020-06-04 | 2021-12-07 | 成都倍特药业股份有限公司 | 一种地塞米松磷酸钠液体制剂及其制备方法 |
| CN116270662A (zh) * | 2021-12-03 | 2023-06-23 | 苏州欧康维视生物科技有限公司 | 盐酸莫西沙星地塞米松磷酸钠滴眼液 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2939873A (en) * | 1959-01-26 | 1960-06-07 | Merck & Co Inc | Synthesis of steroid phosphates |
| US5414011A (en) * | 1987-09-11 | 1995-05-09 | Syntex (U.S.A.) Inc. | Preservative system for ophthalmic formulations |
| US5407926A (en) * | 1987-12-29 | 1995-04-18 | Alcon Laboratories, Inc. | Ophthalmic composition |
| DE3906365A1 (de) * | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
| US5397771A (en) * | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
| IL102414A (en) * | 1991-07-25 | 1996-08-04 | Univ Louisville Res Found | Medicinal preparations for the treatment of ocular inflammation, containing rapamycin |
| ES2079994B1 (es) * | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
| US6716830B2 (en) * | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
| US6740664B2 (en) * | 1998-09-30 | 2004-05-25 | Alcon, Inc. | Methods for treating otic and ophthalmic infections |
| WO2001089495A2 (en) | 2000-05-19 | 2001-11-29 | Alcon Laboratories, Inc. | Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose |
-
2008
- 2008-11-24 US US12/276,823 patent/US7888370B2/en active Active
- 2008-11-24 EP EP08855506A patent/EP2211835A1/en not_active Withdrawn
- 2008-11-24 AU AU2008329876A patent/AU2008329876A1/en not_active Abandoned
- 2008-11-24 CN CN200880116678A patent/CN101861139A/zh active Pending
- 2008-11-24 CA CA2703913A patent/CA2703913A1/en not_active Abandoned
- 2008-11-24 WO PCT/US2008/084532 patent/WO2009070530A1/en not_active Ceased
- 2008-11-24 MX MX2010004953A patent/MX2010004953A/es not_active Application Discontinuation
- 2008-11-24 RU RU2010126096/15A patent/RU2010126096A/ru unknown
- 2008-11-24 KR KR1020107011695A patent/KR20100090278A/ko not_active Withdrawn
- 2008-11-24 JP JP2010535114A patent/JP2011504881A/ja not_active Withdrawn
- 2008-11-24 BR BRPI0819908-6A patent/BRPI0819908A2/pt not_active IP Right Cessation
- 2008-11-26 TW TW097145700A patent/TW200932285A/zh unknown
- 2008-11-27 UY UY31494A patent/UY31494A1/es not_active Application Discontinuation
- 2008-11-27 CL CL2008003536A patent/CL2008003536A1/es unknown
- 2008-11-27 AR ARP080105164A patent/AR069438A1/es not_active Application Discontinuation
-
2010
- 2010-04-23 ZA ZA2010/02884A patent/ZA201002884B/en unknown
- 2010-12-14 US US12/967,250 patent/US8173671B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20090137539A1 (en) | 2009-05-28 |
| US20110082125A1 (en) | 2011-04-07 |
| CN101861139A (zh) | 2010-10-13 |
| US7888370B2 (en) | 2011-02-15 |
| RU2010126096A (ru) | 2012-01-10 |
| ZA201002884B (en) | 2011-07-27 |
| MX2010004953A (es) | 2010-08-10 |
| WO2009070530A1 (en) | 2009-06-04 |
| TW200932285A (en) | 2009-08-01 |
| CL2008003536A1 (es) | 2009-10-16 |
| US8173671B2 (en) | 2012-05-08 |
| CA2703913A1 (en) | 2009-06-04 |
| UY31494A1 (es) | 2009-03-02 |
| JP2011504881A (ja) | 2011-02-17 |
| AU2008329876A1 (en) | 2009-06-04 |
| EP2211835A1 (en) | 2010-08-04 |
| BRPI0819908A2 (pt) | 2015-05-19 |
| KR20100090278A (ko) | 2010-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069438A1 (es) | Formulaciones en solucion que contienen clorhidrato de moxifloxacina y fosfato de dexametasona para uso oftalmico u otico por via topica | |
| ES2584858T3 (es) | Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol | |
| ES2198127T3 (es) | Composiciones farmaceuticas autoclaveables que contienen un agente quelante. | |
| ES2494442T3 (es) | Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico | |
| ES2606342T3 (es) | Composiciones para el cuidado bucal de sal estannosa y tripoli-fosfato de sodio y métodos | |
| MX2009002220A (es) | Sistemas y metodos desinfectantes. | |
| PE20091975A1 (es) | Composiciones de insulina de accion superrapida | |
| AR110010A2 (es) | Composición farmacéutica formulada en una forma de dosis única de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo | |
| AR066905A1 (es) | Administracion intranasal de asenapina y composiciones farmaceuticas correspondientes | |
| PE20030347A1 (es) | Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas | |
| PE20120342A1 (es) | Formulacion de anticuerpo | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| BR0213612A (pt) | Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição | |
| BR112014009031A2 (pt) | formulações de etanercept estabilizadas com íons de metais | |
| PE20010627A1 (es) | Composiciones que tienen estabilidad mejorada | |
| AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
| PE20071310A1 (es) | Formulaciones liquidas de fenilefrina | |
| ES2184310T3 (es) | Formulacion autoemulsionante para compuestos lipofilos acidos. | |
| AR081364A1 (es) | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| CO6220902A2 (es) | Formulacion en polvo del valganciclovir | |
| AR041021A1 (es) | Composicion topica | |
| PE20050822A1 (es) | Derivados de florfenicol con mejor solubilidad en agua | |
| BR112012021638A2 (pt) | composição livre de conservantes estéril ótica farmacêutica na forma de uma solução aquosa clara. | |
| PH12016502100A1 (en) | Liquid formulation comprising gm-csf neutralizing compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |